ANAMAR

AnaMar is a privately held, clinical-stage biotech company developing a first-in-class, orally bioavailable, peripheral-acting 5-HT 2B receptor antagonist, AM1476, as a pan anti-fibrotic medicine... We are combining our innovative therapeutic platform with biomarkers and genetic analysis to identify those patients most likely to benefit from treatment, using our heritage in diagnostics to ensuring the best outcomes for those with fibrosis... We are developing a novel medicine to prevent, heal, and slow organ scarring due to fibrotic disease.

Also known as: AnaMar AB

Primary location: Stockholm Sweden